Aspen Pledges its Support of Equitable Vaccine Access in Africa ASPEN PHARMACARE HOLDINGS LIMITED (Incorporated in the Republic of South Africa) (“Aspen Holdings”) Registration number: 1985/002935/06 Share code: APN ISIN: ZAE000066692 LEI: 635400ZYSN1IRD5QWQ94 and its subsidiaries (collectively “Aspen” or “the Group”) ASPEN PLEDGES ITS SUPPORT OF EQUITABLE VACCINE ACCESS IN AFRICA – GROUP CHIEF EXECUTIVE’S ADDRESS TO HIGH-LEVEL SEMINAR ON MANUFACTURING VACCINES IN AFRICA Shareholders are advised that, on Friday 29 May 2021, Aspen participated in a high-level manufacturing seminar on manufacturing vaccines in Africa, hosted by South African President Cyril Ramaphosa and French President Emmanuel Macron. The dialogue between Presidents Ramaphosa and Macron included discussions with leading scientists and captains of industry about vaccine solutions for Africa, strengthening the local public health systems, addressing the pandemic’s impact on Africa and, in particular, how Africa may expand its own manufacturing capacity to establish security of supply of vaccines across the continent. In his address to attendees, Aspen Group Chief Executive, Stephen Saad, confirmed that Aspen was committed to providing impetus to the common global understanding that “we are not safe until we are all safe”. He also confirmed that it was critical that Africa collaborated with the international community to ensure security of demand, underwritten through long-term offtakes, and the facilitation of technology licenses and transfers. Aspen’s commitment to making sterile manufacturing capacity available for equitable vaccine access to Africa was reiterated and reference was made to multiple engagements with the African Union, the African Centre for Disease Control and other key stakeholders on the contributions Aspen could render in this regard. It was, however, confirmed that this commitment would require a substantial increase of Aspen’s African sterile capacities. His address further confirmed that Aspen had been at the forefront of the fight against other global pandemics including HIV/AIDS, MDR TB and, more recently, COVID-19. Aspen’s contribution to this fight to date has been through its ongoing supply of dexamethasone and lifesaving anaesthetics, playing a leading role in this regard throughout Europe and globally. Aspen was, however, shifting its COVID-19 focus to assist in ensuring equitable access to vaccines for less developed countries, with a particular emphasis on African countries. While Aspen was able to make the required investments to ensure Africa’s reduced reliance on the importation of vaccines, there was a need for certainty on sustainable demand, as well as for assistance with licenses and technology transfers. Aspen’s full press release in this regard can be accessed on its website at the following link: https://www.aspenpharma.com/group-news/ Durban 31 May 2021 Sponsor Investec Bank Limited Date: 31-05-2021 09:15:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on, information disseminated through SENS.